Riociguat
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Pulmonary Arterial Hypertension
Conditions
Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Trial Timeline
Apr 13, 2022 → Aug 13, 2025
NCT ID
NCT04954742About Riociguat
Riociguat is a approved stage product being developed by Merck for Primary Pulmonary Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT04954742. Target conditions include Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04954742 | Approved | Terminated |
Competing Products
20 competing products in Primary Pulmonary Arterial Hypertension